Pre-Market
4 Large Drug Stocks to Hold on to Amid Industry Challenges
After a rather weak 2023, the drug and biotech sector made a comeback initially in 2024 amid a slew of takeover deals. However, the ...
Tesla Pre EPS Turmoil: 3 Long-Term Factors to Consider
Beyond Bitcoin, finding a more controversial, “battleground” investment than Tesla (TSLA) is difficult.Depending on whom you ask and their investment timeframe, the stock is ...
Insights into the Q1 Earnings Prospects of M&T Bank (MTB)
M&T Bank Corporation (MTB) is set to unveil its first-quarter 2024 financial results on April 15, before the morning bell amidst expectations of a ...
Finding Stability in Market Volatility: A Dive into Blue-Chip Retail Stocks
Navigating the tumultuous waters of investment is akin to a tightrope walk, balancing risk and reward. As whispers of potential Federal Reserve policy shifts ...
Acquisition Bonanza: Prosperity Bancshares (PB) Completes Lone Star Acquisition
Prosperity Bancshares, Inc. has solidified its foothold in the financial landscape with the recent conclusion of its merger with Lone Star State Bancshares, Inc. ...
The Value in Holding on to HealthEquity (HQY) Stock
HealthEquity, Inc. HQY, a player in the medical savings and spending sector, has been leveraging its innovative investment platform, particularly its Health Savings Accounts ...
An Electrical Odyssey: General Electric’s GE Arm Secures IFEP Contract in Singapore
The mighty General Electric Company has once again demonstrated its prowess in the electric power domain. This time, the GE Power Conversion arm, under ...
Empowering Innovation: Waters Introduces Game-Changing Software for LC Solutions
Waters‘ stepping-stones in enhancing its liquid chromatography (LC) solutions are turning into mighty leaps, fueled by cutting-edge technological advancements. Revolutionizing Analytical Efficiency In its ...
Portfolio Income Growth Drives PRA Group’s (PRAA) Fourth Quarter Earnings
Portfolio Income Growth Drives PRA Group’s (PRAA) Fourth Quarter Earnings
PRA Group, Inc. (PRAA) reported a fourth-quarter 2023 loss of 22 cents per share, surpassing the Zacks Consensus Estimate. This marks a considerable improvement ...
A Preview of C4 Therapeutics (CCCC) Q4 Earnings
As C4 Therapeutics, Inc. (CCCC) gears up to release its fourth-quarter and full-year 2023 results, investors eagerly anticipate updates on its robust pipeline. The ...
